RenovoRx will hold a conference call on August 12, 2026, to discuss its Q2 financial results and business highlights, including growing sales of its FDA-cleared RenovoCath drug-delivery device and increased adoption at major U.S. cancer centers. The company will also update on its Phase III TIGeR-PaC trial for intra-arterial gemcitabine in pancreatic cancer, expecting full enrollment soon and final data by mid-to-late 2027. RenovoRx continues to advance its oncology pipeline and expand clinical use of its TAMP therapy platform, supported by recent FDA orphan drug designations and ongoing studies. These developments aim to broaden the use of targeted therapies in cancer treatment.
Guangzhou's Nansha District is rapidly advancing as a global cross-border trade hub with its state-of-the-art automated container terminal and integrated multimodal transport system. In 2025, Nansha Port handled over 22.6 million TEUs and operates 18...
Nord Precious Metals Mining Inc., focused on high-grade silver mining in Northern Ontario, announced that CEO Frank J. Basa will present live at the OTCQB Virtual Investor Conference on August 5, 2026. The event allows investors to engage directly wi...
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, effective August 6, 2026. Distribution rates vary widely across ETFs, reflecting different investment strategies and associated risks, including semiconductor, AI, crypto, metals, an...
The global military drone market is expected to grow from $16.5 billion in 2025 to $42.8 billion by 2035, at a CAGR of 10%. Growth is fueled by AI-powered autonomous systems, defense modernization, and rising demand for surveillance, electronic warfa...
Man Group PLC has disclosed a 1.66% interest in Senior Plc's ordinary shares, totaling 6,962,764 shares, held through cash-settled derivatives as of August 3, 2026. The stake was increased by 104,804 shares via an equity swap transaction priced at ap...
